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A sensitive flow cytometric assay has been developed using a monoclonal antibody, Myc 1-6E10, to
quantitate c-myc oncoprotein levels in nuclei isolated from wax embedded testicular tumours. The
oncoprotein (p62cmY) level increased significantly with increasing teratoma differentiation. Patients with
intermediate and undifferentiated tumours who developed recurrence had lower p62cmYC levels than those who
were disease free since their initial treatment. Such quantitative biochemical methods may provide new
prognostic indices for cancer patients.
Oncogenes are highly conserved regions of the
normal genome and over 25 have been identified
and many have also been cloned and sequenced
(Bishop, 1984; Hamlyn & Sikora, 1983). Changes in
either the coding or control regions of these genes
have been implicated in the development of cancer
(Cooper & Lane, 1984; Krontiris, 1983). Several
molecular mechanisms resulting in the increased
production of normal oncogene products or the
development of aberrant proteins which subvert the
normal growth control processes have now been
uncovered (Der & Cooper, 1983; Stewart et al.,
1984). These include gene amplification, trans-
location, mutation, promotor insertion and
rearrangement. Such changes have been
documented in fresh tumour biopsies from patients
as well as cultured cell lines. (Rothberg et al., 1984;
Favera et al., 1982). The N-myc gene has been
found to be amplified up to 100-fold in both
neuroblastoma (Schwab et al., 1983) and retino-
blastoma (Lee et al., 1984) using DNA
hybridization techniques. In one patient with
chronic myelocytic leukaemia, the c-myc sequence
was amplified 16-fold and rearranged within the
genome during episodes of transformation
(McCarthy et al., 1984). Amplification of this gene
has been reported in cell lines derived from a very
poor prognosis group of patients with small cell
lung cancer (Little et al., 1983). K-ras and H-ras
mRNA have been found elevated in colonic
carcinoma, colonic polyps (Spandidos & Kerr,
1984) and breast cancer (Spandidos & Agnantis,
1984). The structure and function of the oncogene
protein products are now under active investigation.
Those of c-sis and v-erb-B respectively code for a
subunit of platelet derived growth factor, PDGF
(Waterfield et al., 1983) and the internal domain of
the epidermal growth factor receptor (Downward et
al., 1984).
Considerable interest has surrounded the ras and
myc genes as marked variation has been found in
the quantity of their transcripts in clinical biopsies
at the RNA level (Slamon et al., 1984). The c-myc
gene product is a 62,000mol.w protein (p62UmYc)
which may be involved in the transition from a
quiescent to an actively dividing state. The level of
c-myc mRNA increases as cells are stimulated into
division (Kelly et al., 1983; Rabbitts et al., 1985;
Makino et al., 1984; Thompson et al., 1985;
Greenberg & Ziff, 1984). Both mRNA transcripts
and the protein itself have unusually short half-lives
of 20 to 30min (Rabbitts et al., 1985; Hann et al.,
1985), a prerequisite for their putative cell
proliferation control function. However, when cells
have entered the cell cycle and protein level remains
constant in G1, S and G2 (Hann et al., 1985;
Rabbitts et al., 1985). Furthermore, the protein
binds to the nucleus, one of the likely sites for
proliferation control (Evan & Hancock, 1985).
DNA and RNA hybridisation analysis is difficult
to perform with many clinical samples. Low copy
number genes and message cannot be detected with
current methods. Hybridisation techniques cannot
normally be applied to fixed embedded material
stored in pathology departments. Furthermore, they
tell us nothing about the ultimate concentration
and distribution in the cell of the final gene
product, the oncoprotein. In order to examine the
relevance of c-myc in clinical samples a set of
mouse monoclonal antibodies was constructed
against the c-myc protein (Evan et al., 1985). One
of these antibodies (Myc-16E10) has been used to
localize p62cmYc in formalin fixed histological
sections from patients with testicular cancer (Sikora
et al., 1985). In this report we show that flow
cytometric quantitation of p62c.mYc using Myc 1-
6E10 in nuclei extracted from paraffin embedded
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testicular cancer biopsies can give prognostic
information.
Materials and methods
Production ofthe anti-p-62CrnYc antibody
Full details for the production and characterisation
of the antibody are given elsewhere (Evan et al.,
1985). Briefly, the DNA base sequence of the
cloned gene was used to determine the amino acid
structure of the protein. Synthetic peptides were
then constructed to regions predicted to be
hydrophillic and hence likely to be exposed on the
surface of the complete molecule. Mice were
immunised with the peptides to produce a number
of monoclonal antibodies (MCAs) which immuno-
precipitate a 62,000 dalton protein identifiable with
the c-myc product. (Evan et al., 1985). One of these
antibodies, Myc 1-6E10 raised to the 18 amino acid
sequence from residues 173-188 (D-peptide), has
been demonstrated to detect p62c-mYc in nuclei
extracted from archival material (Watson et al.,
1985).
35pm nylon mesh to remove debris and clumps,
centrifuged at 200g and resuspended in PBS, pH
7.4 at a concentration of 106 nuclei ml-1.
Aliquots of 1.0ml of the nuclear suspension were
then placed into 1.5ml tubes and spun down in an
Eppendorf centrifuge. The supernatants were
carefully removed and the nuclear pellets were
resuspended in dilutions of Myc 1-6E10. A
fluorescein labelled rabbit and anti-mouse immuno-
globulin was added to probe the Myc 1-6E10 and
the nuclei were counterstained with propidium
iodide (PI) to assess DNA content (Watson et al.,
1985).
The nuclei were analysed in the Cambridge MRC
custom built flow cytometer (Watson, 1980, 1981)
with a high efficiency light collection flow chamber
(Watson, 1985). The Innova-90 argon laser
(Coherent, Palo Alto, CA) was turned to the
488nm line which simultaneously excites red
(DNA) and green (oncoprotein) fluorescence from
individual nuclei. The data were stored on
computer disc and following collection were
recalled for display and analysis. Figure 2 shows an
example of a data set from one patient with
teratoma where a well pronounced aneuploid
Patients
A total of 38 patients attending Addenbrooke's
Hospital with testicular cancer between the years
1967 to 1982 were included in this study. The only
criteria of entry were a minimum follow up of 3
years from diagnosis and that sufficient material
could be obtained from the stored biopsy of the
primary lesion to perform the assay.
Extraction ofnuclei, staining andflow cytometry
The full technical details of our method have been
published (Watson et al., 1985), but for con-
venience, the methodology is summarised in
Figure 1. The paraffin wax embedded biopsies were
obtained from the Department of Pathology and
care was taken, where possible, to check that the
20pm sections used for analysis contained a
majority of tumour tissue. This was effected by
cutting alternate 4pm and 20pm sections and
examining the former histologically. Sufficient
biopsy material was available from 33 of the 38
patients to perform this check and the vast majority
of each section analysed was composed of tumour.
This is consistent with the clinical behaviour of
these lesions which tend to have infiltrated the
majority of the testicular tissue at diagnosis.
Isolated nuclei were extracted by pepsin digestion
after dewaxing and xylene and rehydration. Our
procedure is a modified version of the method
described by Headley et al., (1983). The suspension
containing isolated nuclei was filtered through a
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Figure 1 Schema for nuclear p62c-mYc assay from wax
block material.
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specificity, are shown in Table I. Four monoclonal
antibodies which do not recognise p62cmYc or
nuclear structures gave no significant signal above
background in the two tissue culture lines.
I
DNA
Figure 2 Example of flow cytometric analysis of
p62c-mYc (ordinate) versus total DNA content (abscissa)
from a patient with aneuploid tumour elements. The
first DNA peak corresponds in position to the normal
diploid which is associated with low p62c-mYc levels.
The aneuploid peak is associated with high levels.
component was present. The data are presented as
contour plots of p62c-mYc associated fluorescence
(ordinate) versus DNA fluorescence (abscissa). Note
the higher oncoprotein fluorescence associated with
the aneuploid peak. These data were obtained from
a very small biopsy of the epididymis which was
infiltrated by tumour. The whole of the embedded
specimen was used for the analysis and we can only
infer that the diploid component (35% of the total)
was normal tissue.
Results
Specificity controls for antibody binding and signal
generation were performed. Blocking assays were
carried out with two peptides. The D-peptide,
immunogen for Myc 1-6E10, and the G-peptide
corresponding to the 32 amino acid carboxy
terminus of p62c-mYc (residues 408-439) were used.
Two ,ul of the peptide solutions (1 mgml- 1) were
each added to 20pl antibody (2mgml-1) before use
in the assay, the peptide concentrations being in
considerable excess. The D-peptide completely
blocked antibody binding activity on seminoma,
teratoma and two tissue culture cell lines. The G-
peptide caused only a 14% and 11% decrease in
the Myc 1-6ElO signal in seminoma and teratoma
respectively. These results, which indicate
Table I Results of blocking assay with the D and G
peptides
Seminoma Teratoma
FITC Control 93 136
Myc 1-6E10 489 426
D-peptide blocked 78 102
G-peptide blocked 421 380
The median fluorescence values associated with the
diploid peak in seminoma and the aneuploid peak from a
teratoma are shown for unblocked Myc 1-6E10 and after
addition of the D-peptide (used as the immunogen) and
the G-peptide (corresponding to the carboxy terminus of
p62c-mYc) prior to the assay. Binding was blocked
completely by the D-peptide but the G-peptide caused
only a 14% and 11% signal decrease in seminoma and
teratoma respectively.
An overall summary of p62c-mYc quantitation in
testicular cancer versus clinical outcome is given in
Figure 3. All assays were performed blind and the
median of the p62c-mYc fluorescence distribution
associated with the diploid peak or the aneuploid
component when present (3 patients) was calculated
for each sample. The patients were then divided
into two groups, those who were alive and well
with no recurrence at 3 years after diagnosis and
those who developed recurrence within this interval.
The mean oncoprotein levels in arbitrary
fluorescence units (±s.d.), were 513+275 and
155 +77 for the good and bad prognosis groups
respectively. Student's t-test for comparison of the
means with their variance was 3.4 with 36 degrees
of freedom, P<0.001. The good prognosis group
contained 11 patients with seminoma (open circles
Figure 3) all of whom are alive and well. When this
subset was excluded the mean p62c-mYc level was
456+305 for the teratoma patients who are alive
and well. Comparison of this group with those who
developed recurrence gave t=2.4 and 25 degrees of
freedom, P<0.02.
Comparisons of histological type with p62c-myc are
shown in Figure 4. The mean level from the 11
patients with seminoma was 601+204. Twenty-
seven patients with teratoma were classified into 3
groups: undifferentiated (MTU, 16 patients);
intermediate (MTI, 6 patients) and tumours of
intermediate differentiation with yolk sac elements
(MT+YS, 5 patients). The mean p62c-mYc levels
were 185+119, 340+142 and 862+118 for MTU,
MTI and MT+YS respectively. The mean values
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Figure 3 Comparison of p62cmYc content in nuclei
from biopsies of good and bad prognosis testicular
cancer patients. A/W=alive and well;
R/D=recurrence and dead.
were statistically different for all comparisons at
P<0.05 (see legend Figure 4).
Nine patients with MTU and 1 patient with MTI
died or developed recurrent disease within three
years of diagnosis, the remaining 12 patients have
remained alive and well with no recurrence for at
least 3 years. When the MTU and MTI categories
were combined we found the mean p62c-myc levels in
the good and bad prognosis groups were 288+ 157
and 155 +77 respectively (Figure 5). t-test for
comparison of means was 1.78 with 20 degrees of
freedom, P<0.05.
There was no correlation between p62c-mYc level
and the age of the patient, stage of disease, or
serum levels of human chorionic gonadotrophin.
The pre-treatment alpha foetoprotein levels were
compared with p62C-myc and there was no
correlation in MTU or MTI but a good correlation
with tumours showing yolk sac differentiation.
Only 3 patients exhibited an aneuploid
component on the DNA histogram. All were
teratomas but the numbers are too small to make
any useful observations on the prognostic
significance of aneuploidy in this group of patients.
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Figure 4 p62c-mYc content of tumour biopsy nuclei
from patients with seminoma (sem); malignant
teratoma undifferentiated (MTU); malignant teratoma
intermediate (MTI); malignant teratoma with yolk sac
elements (MT+YS). Differences at the P<0.05 level
of significance were found for comparisons between
seminoma and MTI, seminoma and MT+YS and
between MTI and MTU. Differences between
seminoma and MTU and between MTI and MT+YS
were significant at P<0.005, and between MTU and
MT+YS at P<0.0001.
However, these data sets gave some indication of
p62cmYc levels in normal tissue assuming that the
diploid components were indeed normal. The
diploid peak in Figure 2 had a median p62c-myc level
of 132 after subtracting the corresponding
fluorescence control value. In the remaining two
patients the diploid component comprised 10% and
30% of cells in the sample. These proportions
correlated with the subjective assessment of normal
cell content in the 4 m histological sections. The
p62c-mYc levels in these diploid peaks were 68 and
110 respectively. One further patient, not included
in this study, showed haploid, diploid and
aneuploid components. This clearly was an 'odd-
ball' from the DNA histogram and was later found
to be an interstitial cell tumour. Both the haploid
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Figure 5 Comparison of p62CmYc content in nuclei
from biopsies of good and bad prognosis teratoma
patients after exclusion of the best prognosis group,
those showing yolk sac differentiation. A/W=alive
and well; R/D = recurrence and dead.
and diploid peaks had low p62c-mYc fluorescence, 50
and 90 respectively.
Discussion
We believe this to be the first report of an
oncogene product quantitation in archival biopsies
which has been correlated with morphology and
clinical prognosis. Significant differences were
found for all comparisons between seminoma and
the three histological categories of teratoma. The
p62C-mYc level increased with increasing differen-
tiation in teratoma, and the good prognosis patients
had significantly higher levels than the bad
prognosis group. Presumed normal elements in
biopsies containing aneuploid components had low
p62c-mYc fluorescence with a mean of 90. This
corresponds to the lowest end of the range found in
MTU (Figure 3). Completely normal control
testicular tissue within the age group 15 to 55 years
spanning the ages of patients in this study was,
comfortingly, impossible to find in our pathology
archives. Orchidectomy specimens from patients
with prostatic cancer were plentiful but the majority
of these patients were over 65 and had been treated
with oestrogens. Histologically these specimens were
atrophic and totally unsuitable as controls for the
patients reported here.
The findings in teratoma were completely
contrary to our initial expectation as oncogene
amplification or increased mRNA transcripts have
been found in a number of malignancies (Schwab et
al., 1983; Lee et al., 1984; McCarthy et al., 1984;
Little et al., 1983; Spandidos & Kerr, 1984;
Spandidos & Agnantis, 1984). However, an increase
in either the gene or mRNA copy number (or
both), which should give rise to an increased
protein production rate, need not necessarily be
reflected in a marked increase in the total protein
content for two main reasons. Firstly,
inappropriately increased message may result in
rate limitation at the protein synthesis level.
Secondly, an increase in protein degradation may
offset an increased production rate. The latter is
most likely to occur with a protein which has a
short half-life and clearly, this is a distinct
possibility for p62c-mYc with a half-life of 20-30min
in rapidly cycling and stimulated cells (Rabbitts et
al., 1985; Greenberg & Ziff, 1984). Hence, the lower
absolute levels in undifferentiated teratomas,
compared with the better differentiated tumours,
may reflect an increased protein turnover and an
increased cell production rate in the former. A
further possibility is that post transcriptional
protein modification in the more malignant
tumours may give rise to an alteration or partial
occlusion of the epitope recognised by Myc 1-6E10.
However, these possibilities will not be resolved
with archival data and will probably require the
function of the protein to be elucidated.
In spite of our lack of knowledge of the protein's
function these results demonstrate that there is
considerable potential clinical significance in
quantitating oncogene products in wax embedded
stored biopsy material. The clinical outcome will
already be known in most cases and consequently
prognostic correlates can be discovered rapidly. Our
results using Myc 1-6E10 with immunoperoxidase
staining in teratoma show good agreement between
the quantitative flow cytometric analysis and the
subjective results of immunohistology (Sikora et al.,
1985).
One of our objectives in these studies was to
define quantitative biochemical differences between
good and bad prognosis groups in which the
morphology is very similar or identical. This would
be of direct relevance to patient care by being able
to identify those poor risk patients for whom new
therapeutic schedules would have to be found.
These studies have gone some way to achieving this
by demonstrating a difference between the mean
p62c-mYc levels in the good and bad prognosis
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teratoma groups. Although we have found
significant differences between the prognostic
subsets in teratoma it would not be possible to
predict reliably into which group an individual
would fall from our current data (see Figure 5).
However, c-myc is one of many oncogenes and the
measurement of combinations of these gene
products simultaneously may provide more accurate
prognostic data. Those of the p53, c-fos and c-myb
genes are also nuclear binding and should,
therefore, be amenable to analysis using this
method when suitable MCAs become available.
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